| 104.00 Delayed Data As of Sep 20 |  -0.69 / -0.66%Today’s Change | 84.45 Today|||52-Week Range 278.62 | -23.36% Year-to-Date |
| Ligand (LGND) Surges: Stock Moves 6.3% Higher Sep 13 / Zacks.com - Paid Partner Content |
| Previous close | 104.69 |
| Today’s open | 104.70 |
| Day’s range | 103.09 - 107.67 |
| Volume | 982,986 |
| Average volume (3 months) | 398,118 |
| Market cap | $2.0B |
| Earnings growth (last year) | +1,034.54% |
| Earnings growth (this year) | -54.27% |
| Earnings growth (next 5 years) | +25.00% |
| Revenue growth (last year) | +78.21% |
| P/E ratio | 3.2 |
| Price/Sales | 12.99 |
| Price/Book | 3.85 |
| Today’s change | Today’s % change | |
|---|---|---|
| CBMCambrex Corp | +0.04 | +0.07% |
| AKCAAkcea Therapeutics I... | -0.01 | -0.04% |
| ZGNXZogenix Inc | +0.07 | +0.17% |
| AGIOAgios Pharmaceutical... | +0.27 | +0.75% |
| Next reporting date | October 30, 2019 |
| EPS forecast (this quarter) | $0.61 |
| Annual revenue (last year) | $251.5M |
| Annual profit (last year) | $143.3M |
| Net profit margin | 57.00% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director John L. Higgins |
President & Chief Operating Officer Matthew W. Foehr |
Corporate headquarters San Diego, California |
